Fulcrum Therapeutics (NASDAQ:FULC) Stock Breaks Above Fifty Day Moving Average – Should You Sell?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $3.76 and traded as high as $3.80. Fulcrum Therapeutics shares last traded at $3.77, with a volume of 1,620,682 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Fulcrum Therapeutics Price Performance

The company’s 50 day simple moving average is $3.76 and its 200 day simple moving average is $5.92. The firm has a market cap of $287.65 million, a price-to-earnings ratio of -3.12 and a beta of 2.63.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). As a group, analysts forecast that Fulcrum Therapeutics, Inc. will post -0.60 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FULC. BlackRock Inc. purchased a new stake in Fulcrum Therapeutics during the 2nd quarter worth about $32,297,000. Nantahala Capital Management LLC purchased a new stake in shares of Fulcrum Therapeutics during the second quarter worth approximately $20,038,646. ADAR1 Capital Management LLC acquired a new stake in Fulcrum Therapeutics in the second quarter valued at approximately $5,728,000. Bank of America Corp DE acquired a new stake in Fulcrum Therapeutics in the second quarter valued at approximately $3,817,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Fulcrum Therapeutics in the second quarter worth approximately $2,728,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.

Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.